Daiichi Sankyo's Azor improves 24-hour ABP

Japanese drugmaker Daiichi Sankyo reported data at the 2009 annual meeting of the American Society of Hypertension, in San Francisco,  showing that Azor (amlodipine besylate/olmesartan medoxomil) can  maintain blood pressure reductions over 24 hours.

The AZECT study also demonstrated that the combination drug can be an  effective tool for treating hypertension in more challenging patient  populations, such as patients with type 2 diabetes and  African-Americans.

In the study, Azor provided mean 24-hour ambulatory reductions in  systolic BP of 21.4mmHg and diastolic blood pressure of 12.7mmHg. In  addition, 71% of patients in the trial were able to safely and  effectively achieve a 24-hour ambulatory target BP of <130/80mmHg. The  study also showed large mean 24-hour ambulatory BP reductions in  patients with hypertension from two groups with elevated risk for  developing hypertension, African-Americans (20.7/11mmHg) and type 2  diabetes sufferers (21.5/12.6mmHg).